Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04706663 · ClinicalTrials.gov registry record
Precision-Based Genomics in Prostate Cancer
A clinical trial of Prostate Cancer, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 11
- Study locations
NCT04706663: Recruiting study of Prostate Cancer, sponsored by National Cancer Institute (NCI).
NCT04706663 is a study of Prostate Cancer that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 2,000 participants, above the 606-participant average among 735 other Prostate Cancer trials with a reported enrollment target (230% higher). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04706663, a study of Prostate Cancer, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 11
- Study locations
Study Summary
Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is. Objective: To look at gene mutations in men with prostate cancer as well as the course of their disease to better understand how gene mutations relate to the way the cancer progresses and responds to treatment. Eligibility: Adult males 18 and older with prostate cancer who have at least one of the gene mutations researchers want to study and/or have been treated for their cancer and have had complete elimination of their cancer or stable disease for a long time. Design: Participants will be screened with a review of their medical records. Their gene test results will be reviewed, if available. They will be asked questions over the phone or in person. Participants do not need to visit the NIH for this study. But if they visit NIH for another study, their data and test results will be collected. They may give blood and urine samples. They may give leftover tumor samples. These samples will be used to study their genes. Participants who do not come to NIH on regular basis will be contacted every 6 months by phone or e-mail. They will be asked questions about their health. Data from their medical records will be collected. Participants will have testosterone and prostate-specific antigen (PSA) tests. Participants may be invited to NIH to give blood samples for research. Participants on this study will be followed for life.
Primary Outcome
clinical presentation, patterns of disease progression, therapeutic response, disease recurrence and participant overall survival
Conditions Studied
Study Locations (11)
New York
- Memorial Sloan Kettering Cancer Center - New York
- Mount Sinai Hospital - New York
- Weill Cornell Medicine - New York
California
- University of California San Diego - La Jolla
- University of California San Francisco - San Francisco
Illinois
- NorthShore University HealthSystem - Evanston
Maryland
- National Institutes of Health Clinical Center - Bethesda
Massachusetts
- Dana Farber Cancer Institute, Boston, MA - Boston
Michigan
- University of Michigan - Ann Arbor
Oregon
- Oregon Health Sciences University - Portland
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2021-09-14 |
| Est. Completion | 2027-06-30 |
What NCT04706663 shows while recruiting
NCT04706663 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 606-participant average among 735 other Prostate Cancer trials with a reported enrollment target (230% higher).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT04706663 lists 11 locations in 8 states (New York, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT04706663 about?
NCT04706663 is a clinical study titled "Precision-Based Genomics in Prostate Cancer". Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is. Objective: To look at gene...
What is the current status of trial NCT04706663?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2021-09-14. Estimated completion is 2027-06-30.
What conditions does trial NCT04706663 study?
This clinical trial studies the following conditions: Prostate Cancer.
Who is sponsoring clinical trial NCT04706663?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04706663 being conducted?
This trial has 11 study locations across California, Illinois, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04706663's enrollment target sits among peer trials
2,000 25th of 735 higher than 711 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI